Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Eukaryotic Gene Expression
Factor de Impacto: 2.156 Factor de Impacto de 5 años: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Imprimir: 1045-4403
ISSN En Línea: 2162-6502

Volumes:
Volumen 30, 2020 Volumen 29, 2019 Volumen 28, 2018 Volumen 27, 2017 Volumen 26, 2016 Volumen 25, 2015 Volumen 24, 2014 Volumen 23, 2013 Volumen 22, 2012 Volumen 21, 2011 Volumen 20, 2010 Volumen 19, 2009 Volumen 18, 2008 Volumen 17, 2007 Volumen 16, 2006 Volumen 15, 2005 Volumen 14, 2004 Volumen 13, 2003 Volumen 12, 2002 Volumen 11, 2001 Volumen 10, 2000 Volumen 9, 1999 Volumen 8, 1998 Volumen 7, 1997 Volumen 6, 1996 Volumen 5, 1995 Volumen 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
10 pages

Prostaglandin E—A Powerful Anabolic Agent for Generalized or Site-Specific Bone Formation

Yannis Vrotsos
Department of Periodontology, University of Athens School of Dentistry, Athens, Greece
Scott C. Miller
Division of Radiobiology, University of Utah, Salt Lake City, UT; and 3Department of Cell Biology, University of Massachusetts Medical School, Worcester, MA
Sandy C. Marks, Jr.
Department of Cell Biology, University of Massachusetts Medical Center, Worcester 01655, USA

SINOPSIS

Prostaglandins are locally secreted, rapidly metabolized, biologically active fatty acids first identified in the prostate. The role of prostaglandins in the inflammatory response has been widely studied. However, some prostaglandins, particularly those of the E series (PGEs), can suppress inflammation, making it difficult to understand the local events and their sequence. This bimodal potential of the PGEs has been poorly understood in skeletal biology, causing the initial report of PGEs as mediators of bone resorption to persist for more than two decades, despite ample evidence to the contrary. This resulted in part from the power of any initial report to overrule subsequent conflicting views and in part on the exclusive reliance on in vitro data to explain in vivo phenomena. Over a decade ago, the potential of PGEs as authentic anabolic skeletal agents was demonstrated convincingly in vivo by both systemic and local delivery. The potential clinical applications of the PGEs in skeletal biology have not yet been developed. Our purpose is to review the reasons for the delayed discovery of the true skeletal effects of the PGEs and to describe applications for this technology. With the development of appropriate delivery systems, one can anticipate widespread clinical applications of the PGEs to accelerate skeletal repair, and to treat skeletal pathologies and trauma.


Articles with similar content:

Development of Gene-Based Therapies for Cartilage Repair
Critical Reviews™ in Eukaryotic Gene Expression, Vol.12, 2002, issue 4
Paul D. Robbins, Oliver Betz, Arnulf Pascher, Christopher H. Evans, Steven C. Ghivizzani, Glyn Palmer, Myron Spector, Jean-Noel Gouze, Elvire Gouze
Photodynamic Therapy as an Alternative Antimicrobial Modality for Oral Infections
Journal of Environmental Pathology, Toxicology and Oncology, Vol.25, 2006, issue 1-2
Alexander J. MacRobert, Nurgul Komerik
Surveillance of HPV-Positive Head and Neck Squamous Cell Carcinoma with Circulating and Salivary DNA Biomarkers
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Jordan Cheng, Shreerang Bhide, Hisham Mehanna, Paul Nankivell, Yong Kim, Feng Li, David Wong, Nikolas Batis, Kanishka Rao, Daniele Borsetto, Karl Payne
Concepts in the Design of Artificial Ligaments
Journal of Long-Term Effects of Medical Implants, Vol.10, 2000, issue 3
Bahaa B. Seedhom
Progress Toward Skeletal Gene Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.14, 2004, issue 1&2
Henry J. Klamut, Shin-Tai Chen, David J. Baylink, K.-H. William Lau